Sarepta CEO Doug Ingram buys $2M batch of his biotech's stock; Express Scripts exploring exclusive gene therapy deals
→ Sarepta’s shares $SRPT have climbed fast since Doug Ingram stepped in as CEO and had a chance to do some deals and reap the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
